Targeted attack on lung cancer before surgery: could new drug combo stop recurrence?
NCT ID NCT05472623
Summary
This study aimed to test whether giving a targeted drug called adagrasib, alone or combined with an immunotherapy drug (nivolumab), before surgery could better treat operable non-small cell lung cancer with a specific KRAS G12C mutation. The goal was to see if this approach could kill more of the tumor before it was removed, potentially reducing the chance of the cancer coming back. The trial was designed for patients with stage IB-IIIA lung cancer but was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.